1248081-37-9

Usage

Uses

Used in Pharmaceutical Industry:
8-(TRIFLUOROMETHYL)-1,4-DIOXASPIRO[4.5]DECAN-8-OL is used as a building block for the synthesis of various pharmaceuticals due to its unique spiro structure and fluorine substitution. Its reactivity and versatility make it a valuable intermediate for developing new compounds with potential biological activity.
Used in Agrochemical Industry:
8-(TRIFLUOROMETHYL)-1,4-DIOXASPIRO[4.5]DECAN-8-OL is also used as a building block in the synthesis of agrochemicals, where its unique structure and reactivity contribute to the development of new compounds with potential applications in agriculture.
Used in Organic Synthesis:
8-(TRIFLUOROMETHYL)-1,4-DIOXASPIRO[4.5]DECAN-8-OL is used as a versatile and useful compound in organic synthesis, thanks to its hydroxyl group that provides reactivity for further functionalization.

Upstream product

• 4746-97-8 cyclohexanedione monoethylene ketal 
• 81290-20-2 (trifluoromethyl)trimethylsilane 

Downstream Products

• 75092-00-1 4-(trifluoromethyl)cyclohexanone (2,4-dinitrophenyl)hydrazone 
• 75091-99-5 4-(trifluoromethyl)cyclohexan-1-one 
• 1346555-40-5 4-(cyclopropylamino)-1-(trifluoromethyl)cyclohexanol 
• 1346554-38-8 N-cyclopropyl-N-((1s,4s)-4-hydroxy-4-(trifluoromethyl)cyclohexyl)-6-(piperidin-1-yl)picolinamide 
• 1346555-38-1 N-cyclopropyl-N-((1r,4r)-4-hydroxy-4-(trifluoromethyl)cyclohexyl)-6-(piperidin-1-yl)picolinamide 
• 1202411-98-0 4-amino-1-(trifluoromethyl)cyclohexan-1-ol 
• 120929-90-0 4-hydroxy-4-(trifluoromethyl)cyclohexan-1-one 

Relevant academic research and scientific papers

COMPOUNDS USEFUL AS KINASE INHIBITORS

This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK).The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.

Synthesis and biological evaluation of picolinamides as potent inhibitors of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1)

Synthesis of a series of 6-substituted picolinamide derivatives and their inhibitory activities against 11β-hydroxysteroid dehydrogenase type 1 are described. Optimization of the initial hit compound, N-cyclohexyl-6-(piperidin-1-yl)picolinamide (1) from high throughput screening of in-house library resulted in the discovery of the highly potent and metabolically stable compound 25, which was efficacious in a mouse ex vivo pharmacodynamic model and reduced the fasting blood glucose and insulin levels in a HF/STZ mouse model after oral dosing.

SUBSTITUTED 3-(BIPHENYL-3-YL)-4-HYDROXY-8-METHOXY-1-AZASPIRO[4.5]DEC-3-EN-2-ONE

The invention relates to substituted 3-(biphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-ones, in particular for therapeutic purposes, to pharmaceutical compositions and to their use in therapy, in particular for the prophylaxis and therapy of neoplastic disorders.

PICOLINAMIDE AND PYRIMIDINE-4-CARBOXAMIDE COMPOUNDS, PROCESS FOR PREPARING AND PHAMACEUTICAL COMPOSITION COMPRISING THE SAME

Provided are picolinamide and pyrimidine-4-carboxamide compounds, a method for preparing the same, a pharmaceutical composition containing the same, and a medical use using the compound as an agent for preventing, regulating, and treating diseases related to regulation of glucocorticoids by using selective inhibitory activity of the compound for an 11β-HSD1 enzyme. The picolinamide and pyrimidine-4-carboxamide compounds of the present invention are selective inhibitors of human-derived 11β-HSD1 enzymes, and are useful in an agent for preventing, regulating, and treating diseases related to glucocorticoid regulation in which human- derived 11β-HSD1 enzymes are involved, for example, metabolic syndromes such as, type 1 and type 2 diabetes, diabetes later complications, latent autoimmune diabetes adult (LAD A), insulin tolerance syndromes, obesity, impaired glucose tolerane (IGT), impaired fasting glucose (IFG), damaged glucose tolerance, dyslipidemia, atherosclerosis, hypertension, etc.

Spectroscopic and X-ray crystallographic evidence for electrostatic effects in 4-substituted cyclohexanone-derived hydrazones, imines, and corresponding salts

The axial conformer of several 4-substituted cyclo-hexanone hydrazone salts was found to predominate in solution. Changes in the charge of the molecule and the polarity of the solvent led to changes in the conformational preference of each molecule that were consistent with electrostatic stabilization of the axial conformer. H NMR spectroscopic analysis was utilized to determine the structure of cyclohexanone-derived substrates by comparison to conformationally restricted trans-decalone derivatives and computational models. X-ray crystallography demonstrated that the axial configuration of a pendant benzyloxy group is the preferred conformation of an iminium ion in the solid state. The structure of a neutral hydrazone was also determined to favor the axial configuration for a pendant benzyloxy group in the solid state.